Top Markets
#1 Cortex Cortex +33.23%
#2 DexNet DexNet +23.20%
#3 龙虾 (Lobster) 龙虾 (Lobster) +20.86%
#4 wojak wojak +17.61%
#5 Akedo Akedo +15.36%
#6 Pons Pons +14.76%
#7 OpenEden OpenEden +11.18%
#8 EXOD EXOD +9.04%
#9 Official Trump Official Trump +8.63%
#10 The Black Bull The Black Bull +8.63%
Coin of the day
Cortex Cortex
Settings
Language
ENGLISH
Currency
USD
Theme
Pharma Mar, S.A. Pharma Mar, S.A.

Pharma Mar, S.A.

PHM
Rank in Stocks #7110
Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and... Pharma Mar, S.A., a biopharmaceutical firm established in 1986 and headquartered in Madrid, Spain, is dedicated to the research, development, production, and global sale of marine-derived bioactive compounds. Its primary focus is oncology, with operations spanning Spain, Italy, Germany, Ireland, the wider European Union, the United States, and other international markets. The company's activities are organized into three key segments: Oncology, Diagnostics, and RNA interference. Among its developed and commercialized treatments are Yondelis, prescribed for soft tissue sarcomas and ovarian cancer; Aplidin, targeting multiple myeloma; and Zepzelca, used for patients with small cell lung cancer. Furthermore, Pharma Mar is advancing PM14, currently in Phase II clinical trials for various solid tumors. Beyond pharmaceuticals, the company manufactures and markets diagnostic kits and is involved in creating therapeutic drugs designed to reduce or silence gene expression.
Share Price
$99.16
Last synced: 2026-08-27
Market Cap
$1.72B
Change (1 day)
0.00%
Change (1 year)
2.52%
Country
ES
Trade Pharma Mar, S.A. (PHM)

Category

Healthcare
Revenue for Pharma Mar, S.A. (PHM)
Revenue in Aug 2026 TTM: 0
According to Pharma Mar, S.A. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Pharma Mar, S.A. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH